Inmune Bio (INMB) Cash from Investing Activities (2025)
Inmune Bio (INMB) posted Cash from Investing Activities of -$143000.0 for Q4 2025, up 25.91% sequentially from -$193000.0 in Q3 2025.
Inmune Bio (INMB) Cash from Investing Activities (2025) Analysis & Trends
Inmune Bio has reported Cash from Investing Activities for 1 years, with the latest figure at -$143000.0 in Q4 2025.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$143000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$336000.0 (changed N/A YoY) and the FY2025 annual result came in at -$1.0 million, changed N/A from the prior year.
- Cash from Investing Activities rose to -$143000.0 in Q4 2025 per INMB's latest filing, from -$193000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$143000.0 in Q4 2025 and troughed at -$193000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -143,000.00 |
| Dec 31, 2025 | -143,000.00 |
| Sep 30, 2025 | -193,000.00 |
| Sep 30, 2025 | -193,000.00 |